Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
  • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/56—Amides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/62—Oxygen or sulfur atoms
  • C07D213/63—One oxygen atom
  • C07D213/65—One oxygen atom attached in position 3 or 5
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/72—Nitrogen atoms
  • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
  • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
  • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/34—One oxygen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/42—One nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
  • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
  • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
  • C07D295/182—Radicals derived from carboxylic acids
  • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
  • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
  • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
  • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
  • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
  • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
  • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
  • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
  • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/08—Bridged systems

Definitions

• This invention relates to heterocyclic compounds that are useful as antagonists of CXCR3 and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the interaction of CXCR3 and its ligands including multiple sclerosis, psoriasis, rheumatoid arthritis, inflammatory bowel disease and atherosclerosis.
• This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
• Chemokine receptors a subclass of the G-protein coupled receptors (GPCRs) are expressed on the surface of T-cells and other leukocytes.
• GPCRs G-protein coupled receptors
• the interaction of chemokine receptors with their ligands plays an important role in the migration of leukocytes to sites of inflammation (A. D. Luster, New Engl. J. Med., 1998, 338, 436).
• the chemokine receptor CXCR3 is preferentially expressed on T helper (ThI) cells but is also found on natural killer cells and subsets of dendritic cells.
• chemokine ligands for CXCR3 have been identified: Mig (Monokine Induced by ⁇ -IFN/CXCL9), IP-IO ( ⁇ - interferon inducible protein) and I-TAC (IFN-Inducible T Cell ⁇ Chemoattractant /CXCRI l) (K.E. Cole et al, J. Exp. Med., 1998, 187, 2009; Y. Weng et al, J. Biol.Chem., 1998, 273, 18288).
• CXCR3 and IP-IO deficient mice also suggest a role for CXCR3 and IP-IO in ThI mediated disease.
• CXCR3 -/- mice showed significant resistance to allograft rejection (W.W. Hancock et al., J. Exp. Med., 2000, 192, 1515).
• IP-10 deficient mice showed protection against the development of colitis (U. P. Singh et al., J. Immunol., 2003, 171, 1401).
• Further evidence of a role for CXCR3 and IP-10 as mediators of disease is provided by studies utilizing blocking antibodies. For example in a rat model of adjuvant induced arthritis (I. Salomon et al., J.
• CXCR3 knockout mice showed alleviated inflammation compared to wild type mice in cigarette smoke induced pulmonary injury as well as lower influx of inflammatory T cells.
• CXCR3 knockout mice showed reduced influx of T cells, less severe nephritis and improved renal function compared to wild type mice (U. Panzer et al., J. Am. Soc. Nephrol, 2007, 18, 2071).
• CXCR3 may play a role in inflammatory pulmonary diseases such as COPD and inflammatory kidney disease.
• inhibitors of CXCR3 may be useful in treating inflammatory and autoimmune diseases in which CXCR3-mediated cellular recruitment plays a role, including multiple sclerosis, psoriasis, rheumatoid arthritis, inflammatory bowel disease, COPD and kidney disease.
• CXCR3 in the pathogenesis of atherosclerosis.
• CXCR3 was found expressed in all T lymphocytes within human atherosclerotic lesions.
• the ligands IPlO, Mig and I- TAC were all found within lesion-associated cells including endothelial and smooth muscle cells (Mig and I- TAC) and macrophages (IPlO), suggesting these ligands play a role in recruitment of activated T lymphocytes within vascular wall lesions in athero genesis.
• Atherosclerosis can result in narrowing of the lumen of the artery and plaque rupture which can lead to coronary heart disease, myocardial infarction and stroke (J. Sanz and Z. A. Fayad, Nature, 2008, 451, 953).
• ApoE "7" background resulted in a significant reduction in atherosclerotic lesion formation following ten weeks on a high cholesterol diet (N. R. Veillard et al., Circulation, 2005, 112, 870). Moreover, deletion of the CXCR3 ligand, IP-IO on an ApoE "7” background similarly reduced atherosclerotic lesion load (E. Heller et al., Circulation, 2006, 113, 2301). More recently, NBI-74330 a CXCR3 antagonist was dosed prophylactically in a LDL receptor knockout model.
• the present invention provides novel compounds which block the interaction of CXCR3 and its ligands and are thus useful for treating diseases and disorders that are mediated or sustained through the activity of CXCR3 including multiple sclerosis, psoriasis, rheumatoid arthritis, inflammatory bowel disease, COPD, kidney disease and atherosclerosis, myocardial infarction and stroke.
• This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
• B is C or N
• D is C or N
• X is -NH- , -NHC(O)-, -N(CH 3 )C(O)- or absent;
• R 1 is H, -CN, halogen, -CF 3 , -OCF 3 , C 1-3 alkyl, C 1-3 alkoxy, -S(O) n CH 3 , amino, mono- or dimethylamino, -NHC(O)Ci- 3 alkyl, -NO 2 , -C(O)NH 2 , -C(O)NHCi- 3 alkyl or -C(O)C 1 . 3 alkyl;
• R 2 is aryl or heteroaryl, each optionally substituted with one to three R 6 ;
• R 3 is heteroaryl, heterocyclyl, aryl or C 3 _iocycloalkyl each optionally substituted with one to three R
• R 4 and R 5 are each independently selected from H and Ci_ 2 alkyl; or R 4 and R 5 may join to form an ethyl bridge;
• each R 6 is independently -OH, oxo, hydroxyCi- ⁇ alkyl, halogen, -(CH 2 ) m -CN, nitro, C 1 - O alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C 3-1 O cycloalkyl, C 1 -O alkoxy, phenoxy, heteroaryloxy, Ci- 6 alkoxycarbonyl, carboxyl, -C(O)C i_ 6 alkyl, -(CH 2 ) m -NR 8 R 9 , -S(O) n C 1 _ 6 alkyl, -NHS(O) n C 1 .
• each R 7 is independently C 1 -O alkyl, C2-6 alkenyl, C2-6
• R 8 and R 9 are each independently hydrogen, C 1 - O alkyl, C 1 - O acyl, C 3-1O cycloalkyl, hydroxyCi-6 alkyl, C 1 -O alkylCi-6 alkoxy, C 1 -O alkylsulfonyl or C 1 -O alkoxycarbonyl;
• n 0-3;
• n 0-2;
• A is N and may be a single or double bond if A is C;
• X is absent
• R 1 is H, -CN, -F, -Cl, -CF 3 , -CH 3 , -OCH 3 , -C(O)NHCH 3 Or -S(O) 2 CH 3 ;
• R 4 and R 5 are H
• each R 6 is independently -OH, oxo, hydroxyCi- ⁇ alkyl, halogen, -(CH 2 ) I11 -CN, nitro, C 1 - O alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, C 3 _ lo cycloalkyl, C 1 - O alkoxy, phenoxy, pyridyloxy, C 1 - O alkoxycarbonyl, carboxyl, -C(O)d_ 6 alkyl, -(CH 2 ) m -NR 8 R 9 , -S(O) n Ci_ 6 alkyl, -NHS(O) 2 Ci.
• each R 7 is independently Ci-6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C 3 _io cycloalkyl, Ci-6 alkoxy, halogen, oxo, -CN, carboxy, -(CH 2 ) m -NR 8 R 9 , phenyl or pyridyl, wherein each alkyl, alkenyl or alkynyl of said R 7 is optionally partially or fully halogenated;
• R 8 and R 9 are each independently hydrogen, Ci-6 alkyl, Ci-6 acyl or C 3 _io cycloalkyl;
• X is -NH- or absent
• R 1 is H, -CN, -F, -Cl, -CF 3 , -CH 3 or -OCH 3 ;
• R 2 is benzoimidazolyl, benzooxazolyl, imidazolyl, lH-imidazo[4,5-c]pyridinyl, indolyl, isoindolyl, isoquinolinyl,isoxazolyl, oxazolyl, phenyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, quinolinyl, thiadiazolyl, thiazolyl or thienyl, wherein each of the foregoing is optionally substituted by one to three R 6 ;
• R 3 is benzoimidazolyl, benzotriazolyl, imidazolyl, imidazo[4,5-b]pyridinyl, indazolyl, indolyl, isoindolyl, isothiazolyl, pyrazolyl, pyridinyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,2-b]pyridinyl, pyrrolo[2,3- d]pyrimidinyl, pyrrolyl, thiadiazolyl or thiazolyl wherein each of the foregoing is optionally substituted with one to three R 7 ;
• each R 6 is independently -CH 2 OH, -Cl, -F, -CN, oxo, Cr 6 alkyl, C 3-6 cycloalkyl, Cr 2 alkoxy, phenoxy, pyridyloxy, -C(O)CH 3 , -(CH 2 ) m -NR 8 R 9 , -S(O) n CH 3 , -NHS(O) 2 CH 3 , _NH(C0)CH 3 , -S(O) 2 NR 8 R 9 , -C(O)NR 8 R 9 , thienyl, morpholinyl, pyrrolidinyl, piperidinyl, [l,3]-oxazepan-l-yl, piperazinyl.
• each alkyl of said R 6 is optionally partially or fully halogenated and each heterocyclyl or phenyl of said R 6 is optionally substituted with one to three CH 3> -OCH 3 , halogen, -CN, -CF 3 , N(CH 3 ) 2 , -C(O)NH 2 , -C(O)NHCH 3 , -OH, -CH 2 OCH 3 , -C(OH)(CH 3 )CH 3 , pyrrolidinyl or S(O) 2 CH 3 ;
• each R 7 is independently Cr 3 alkyl, -OCH 3 , CF 3 , oxo, -CN, -Cl or -F;
• R 8 and R 9 are each independently hydrogen, C 1 -O alkyl, Cr 3 acyl or C 3 _6 cycloalkyl;
• X is absent
• R 3 is benzoimidazolyl, benzotriazolyl, imidazolyl, imidazo[4,5-b]pyridinyl, indazolyl, indolyl, isoindolyl, pyrazolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,2-b]pyridinyl or pyrrolyl, wherein each of the foregoing is optionally substituted with one to three R 7 ;
• the invention relates to a compound selected from compounds described in Table 1, or the pharmaceutically acceptable salts thereof. In another embodiment there is a compound selected from
• the invention relates to a compound selected from: 3-(2-Methylsulfanyl-pyrimidin-5-yl)-4-[4-(2-pyrrolo[2,3-b]pyridin-l-yl-acetyl)- piperazin- 1 -yl] -benzonitrile; 1 - ⁇ 4- [2-(2-Methylsulfanyl-pyrimidin-5-yl)-phenyl] -piperazin- 1 -yl ⁇ -2-pyrrolo[2,3- b]pyridin-l-yl-ethanone;
• the invention also relates to pharmaceutical preparations, containing as active substance one or more compounds of the invention, or the pharmaceutically acceptable derivatives thereof, optionally combined with conventional excipients and/or carriers.
• Compounds of the invention also include their isotopically-labelled forms.
• An isotopically-labelled form of an active agent of a combination of the present invention is identical to said active agent but for the fact that one or more atoms of said active agent have been replaced by an atom or atoms having an atomic mass or mass number different from the atomic mass or mass number of said atom which is usually found in nature.
• isotopes which are readily available commercially and which can be incorporated into an active agent of a combination of the present invention in accordance with well established procedures, include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, e.g., 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 Cl, respectively.
• An active agent of a combination of the present invention, a prodrug thereof, or a pharmaceutically acceptable salt of either which contains one or more of the above-mentioned isotopes and/or other isotopes of other atoms is contemplated to be within the scope of the present invention.
• the invention includes the use of any compounds of described above containing one or more asymmetric carbon atoms may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Isomers shall be defined as being enantiomers and diastereomers. All such isomeric forms of these compounds are expressly included in the present invention. Each stereogenic carbon may be in the R or S configuration, or a combination of configurations. Some of the compounds of the invention can exist in more than one tautomeric form. The invention includes methods using all such tautomers.
• C 1 - O alkoxy is a C 1 - O alkyl with a terminal oxygen, such as methoxy, ethoxy, propoxy, butoxy.
• All alkyl, alkenyl, and alkynyl groups shall be understood as being branched or unbranched where structurally possible and unless otherwise specified. Other more specific definitions are as follows:
• one or more carbon atoms can be optionally replaced by heteroatoms such as O, S or N. It shall be understood that if N is not substituted then it is NH. It shall also be understood that the heteroatoms may replace either terminal carbon atoms or internal carbon atoms within a branched or unbranched carbon chain.
• Such groups can be substituted as herein above described by groups such as oxo to result in definitions such as but not limited to: alkoxycarbonyl, acyl, amido and thioxo.
• nitrogen and “sulfur” include any oxidized form of nitrogen and sulfur and the quaternized form of any basic nitrogen. For example, for a -S-C 1 - O alkyl radical, unless otherwise specified, shall be understood to include -S(O)-C 1 - O alkyl and -S(O) 2 -C L6 alkyl.
• C 3-1O cycloalkyl refers to a nonaromatic 3 to 10-membered (but preferably, 3 to 6-membered) monocyclic carbocyclic radical or a nonaromatic 6 to 10-membered fused bicyclic, bridged bicyclic, or spirocyclic carbocyclic radical.
• the C 3-1 Q cycloakyl may be either saturated or partially unsaturated, and the carbocycle may be attached by any atom of the cycle which results in the creation of a stable structure.
• Non-limiting examples of 3 to 10-membered monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptanyl, cycloheptenyl, and cyclohexanone.
• Non-limiting examples of 6 to 10-membered fused bicyclic carbocyclic radicals include bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, and bicyclo[4.4.0]decanyl (decahydronaphthalenyl).
• Non-limiting examples of 6 to 10-membered bridged bicyclic carbocyclic radicals include bicyclo [2.2.2]heptanyl, bicyclo[2.2.2]octanyl, and bicyclo[3.2.1]octanyl.
• Non-limiting examples of 6 to 10-membered spirocyclic carbocyclic radicals include but are not limited to spiro[3,3]heptanyl, spiro[3,4]octanyl and spiro[4,4]heptanyl.
• aryl refers to an aromatic hydrocarbon rings containing from six to ten carbon ring atoms (e.g., a C 6-1 O aryl).
• C 6-1 O aryl includes monocyclic rings and bicyclic rings where at least one of the rings is aromatic.
• Non-limiting examples of C 6-1O aryls include phenyl, indanyl, indenyl, benzocyclobutanyl, dihydronaphthyl, tetrahydronaphthyl, naphthyl, benzocycloheptanyl and benzocycloheptenyl.
• heterocyclyl refers to a "5 to 11-membered heterocycle” and includes stable nonaromatic 4-8 membered monocyclic heterocyclic radical or a stable nonaromatic 6 to 11-membered fused bicyclic, bridged bicyclic or spirocyclic heterocyclic radical.
• the 5 to 11-membered heterocycle consists of carbon atoms and one or more, preferably from one to four heteroatoms chosen from nitrogen, oxygen and sulfur.
• the heterocycle may be either saturated or partially unsaturated.
• Non-limiting examples of nonaromatic 4-8 membered monocyclic heterocyclic radicals include tetrahydrofuranyl, azetidinyl, pyrrolidinyl, pyranyl, tetrahydropyranyl, dioxanyl, thiomorpholinyl, I,l-dioxo-l ⁇ 6 -thiomorpholinyl, morpholinyl, piperidinyl, piperazinyl, and azepinyl.
• Non-limiting examples of nonaromatic 6 to 11-membered fused bicyclic radicals include octahydroindolyl, octahydrobenzofuranyl, and octahydrobenzothiophenyl.
• Non-limiting examples of nonaromatic 6 to 11-membered bridged bicyclic radicals include 2-azabicyclo[2.2.1]heptanyl, 3- azabicyclo[3.1.0]hexanyl, and 3-azabicyclo[3.2.1]octanyl.
• Non-limiting examples of nonaromatic 6 to 11-membered spirocyclic heterocyclic radicals include 7-aza- spiro[3,3]heptanyl, 7-spiro[3,4]octanyl, and 7-aza-spiro[3,4]octanyl.
• heteroaryl' refers to a "5 to 11-membered heteroaryl” and includes aromatic 5 to 6-membered monocyclic heteroaryls and aromatic 7 to 11- membered heteroaryl bicyclic rings where at least one of the rings is aromatic, wherein the heteroaryl ring contains 1-4 heteroatoms such as N, O and S.
• Non-limiting examples of 5 to 6-membered monocyclic heteroaryl rings include furanyl, oxazolyl, isoxazolyl, oxadiazolyl, pyranyl, thiazolyl, pyrazolyl, pyrrolyl, imidazolyl, tetrazolyl, triazolyl, thienyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, and purinyl.
• Non-limiting examples of 7 to 11-membered heteroaryl bicyclic rings include benzimidazolyl, l,3-dihydrobenzoimidazol-2-one, quinolinyl, dihydro-2H-quinolinyl, isoquinolinyl, quinazolinyl, indazolyl, thieno[2,3-d]pyrimidinyl, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzofuranyl, benzopyranyl, benzodioxolyl, benzoxazolyl , benzothiazolyl, pyrrolo[2,3-b]pyridinyl, , and imidazo[4,5-b]pyridinyl.
• heterocyclyl or heteroaryl contains a S ring atom
• S ring atom can be present in the ring in its divalent, tetravalent, or hexavalent form, i.e., -S-, -S(O)- Or -S(O) 2 -.
• Each aryl or heteroaryl unless otherwise specified includes it's partially or fully hydrogenated derivatives.
• quinolinyl may include decahydroquinolinyl and tetrahydroquinolinyl
• naphthyl may include its hydrogenated derivatives such as tetrahydranaphthyl.
• Other partially or fully hydrogenated derivatives of the aryl and heteroaryl compounds described herein will be apparent to one of ordinary skill in the art.
• heteroatom as used herein shall be understood to mean atoms other than carbon such as O, N, and S.
• halogen as used in the present specification shall be understood to mean bromine, chlorine, fluorine or iodine.
• alkyl a non-limiting example would be -CH 2 CHF 2 , -CF 3 etc.
• the compounds of the invention are only those which are contemplated to be 'chemically stable' as will be appreciated by those skilled in the art.
• a compound which would have a 'dangling valency', or a 'carbanion' are not compounds contemplated by the inventive methods disclosed herein.
• the invention includes pharmaceutically acceptable derivatives of compounds of formula (I).
• a "pharmaceutically acceptable derivative” refers to any pharmaceutically acceptable salt or ester, or any other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound useful for the invention, or a pharmacologically active metabolite or pharmacologically active residue thereof.
• a pharmacologically active metabolite shall be understood to mean any compound of the invention capable of being metabolized enzymatically or chemically. This includes, for example, hydroxylated or oxidized derivative compounds of the invention.
• Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
• suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfuric, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2- sulfuric and benzenesulfonic acids.
• Other acids, such as oxalic acid while not themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds and their pharmaceutically acceptable acid addition salts.
• Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal
• prodrugs of compounds of the invention include those compounds that, upon simple chemical transformation, are modified to produce compounds of the invention. Simple chemical transformations include hydrolysis, oxidation and reduction. Specifically, when a prodrug is administered to a patient, the prodrug may be transformed into a compound disclosed hereinabove, thereby imparting the desired pharmacological effect.
• the compounds of formula (I) may be made using the general synthetic methods described below, which also constitute part of the invention.
• the compounds of the invention may be prepared by the methods described below.
• the groups R 1 to R 5 , A, B, D and X are as defined above for general formula (I) unless noted otherwise.
• Optimum reaction conditions and reaction times may vary depending on the particular reactants used. Unless otherwise specified, solvents, temperatures, pressures and other reaction conditions may be readily selected by one of ordinary skill in the art. Amide bond formations may be carried out by standard coupling conditions well-known in the art (see, for example, M.
• Bodanszky The Practice of Peptide Synthesis (Springer- Verlag: 1984), which is hereby incorporated by reference in its entirety), for example, by reacting a carboxylic acid and an amine in the presence of l-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and 1-hydroxybenzotriazole. Specific procedures are provided in the Synthetic Examples section. Typically, reaction progress may be monitored by thin layer chromatography (TLC) or HPLC-MS if desired. Intermediates and products may be purified by chromatography on silica gel, recrystallization, HPLC and/or reverse phase HPLC.
• TLC thin layer chromatography
• HPLC-MS HPLC-MS
• intermediate II where P is a suitable amine protecting group such as a t-Boc (te/t-butoxycarbonyl) group
• intermediate III a boronic acid bearing R 2
• Suzuki-Miyaura coupling conditions see for example, F. Bellina et al., Synthesis, 2004, 2419-2440.
• Removal of the protecting group for example by treatment with acid if P is a t-Boc group, provides intermediate V.
• Coupling intermediate V with carboxylic acid intermediate VI under peptide coupling conditions known in the art for example by reacting in the presence of O-(Benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) and a suitable base such as di-isopropylethylamine in a suitable solvent such as methylene chloride provides the desired compound of formula (I).
• TBTU O-(Benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
• a suitable base such as di-isopropylethylamine
• a suitable solvent such as methylene chloride
• the peptide coupling with carboxylic acid may be carried out with intermediate VII bearing a Br substituent or similar functionality capable of undergoing the Suzuki-Miyaura coupling, for example a Cl, I or triflate substituent, providing intermediate VIII.
• Intermediate VIII is then coupled with intermediate III to provide the desired compound of formula (I).
• Scheme 4 illustrates an alternate procedure, useful for preparing compounds of formula (I) where R is benzoimidazole, benzooxazole or benzothiazole.
• intermediate VI is coupled with intermediate XIV, where R is an alkyl group such as methyl or ethyl, as described in Scheme 2, followed by hydrolysis of the ester, for example, by treatment with aqueous NaOH in THF/MeOH, to provide XVII.
• Intermediate XVII is then coupled with intermediate XVII, where Y is NH 2 , OH, or SH, to provide intermediate XIX.
• Cyclization for example by heating in a suitable solvent such as dichloroethane in the presence of a suitable catalyst such as p-TsOH, provides the desired compound of formula (I) where Y is NH, O, or S.
• Isoamyl nitrite (0.76 mL, 5.68 mmol) is added dropwise to an ice-bath cooled solution of the above amine intermediate (1.40 g, 4.05 mmol) in dried acetonitrile (20 mL) under nitrogen. The resulting mixture turns light yellow during addition. The reaction is allowed to stir at 0 0 C for 20 min. Then CuBr (872 mg, 6.08 mmol) is added in small portions. The reaction gradually turns to dark green. It is allowed to warm up to ambient temperature in 30 min and stirred overnight.
• the crude product is purified using biotage chromatography eluting with 0-50% EtOAc/hexane. Removal of the solvent provides 1- [4-(2-bromo-4-trifluoromethyl-phenyl)-piperazin-l-yl]-2-pyrrolo[2,3-b]pyridin-l-yl- ethanone as a colorless foam (268 mg, 79%).
• the crude product is purified using biotage eluting with 0-30% EtOAc/Hexane.
• the desired mono-coupled product elutes at 30% EtOAc.
• the di- coupled by-product elutes earlier. Removal of the solvent gives 4-[5-(2-bromo-phenyl)- pyrimidin-2-yl]-morpholine as a white solid (130 mg, 39%).
• 2-Piperazin-l-yl-benzoic acid (1.00 g, 4.89 mmol) is suspended in 10 mL of MeOH.. To this is added 5 mL of cone. H 2 SO 4 . The mixture is stirred for 16 h resulting in a white precipitate. The reaction volume is increased by an additional 210 rnL of MeOH and 65 rnL of H 2 SO 4 . The mixture stirred for 2 h at room temperature and then heated at reflux for 12 h. The reaction volume is concentrated to approximately 175 mL and applied to an ion exchange column, eluting with 5 x 200 mL of 10% NH 3 /Me0H. The product fractions are concentrated and then co-evaporated with toluene to remove residual water providing 0.667 g of 2-piperazin-l-yl-benzoic acid methyl ester.
• N-(2-amino-phenyl)-2- ⁇ 4-[2-(3,5-dimethyl-pyrazol-l-yl)-acetyl]-piperazin-l-yl ⁇ - benzamide (0.050 g, 0.116 mmol) is dissolved into 2 rnL of dichloroethane and placed in a microwave tube. To this is added a catalytic amt. of p-TsOH. The mixture is heated in a microwave at 130° C for 20 min and then 160° C for 30 min. The reaction mixture is concentrated to dryness and the product is purified using a Gilson Prep HPLC system eluting with 20%-100% CH 3 CN/H 2 O) to give 43 mg of desired product.
• Impure fractions are concentrated and purified using a SiO2 prep plate eluting with (5% MeOHZCH 2 Cl 2 ) to give an additional 17.5 mg of l- ⁇ 4-[2-(lH-benzoimidazol-2-yl)-phenyl]-piperazin-l-yl ⁇ - 2-(3,5-dimethyl-pyrazol-l-yl)-ethanone.
• Piperazin-1-yl-benzoic acid (2.00 g, 9.79 mmol) is suspended in 100 niL Of CH 2 Cl 2 .
• diisopropylethyl amine (2.22 niL, 12.00 mmol)
• BOC anhydride (2.07 g, 9.50 mmol).
• the mixture remains heterogeneous after Ih.
• An additional 100 mL of anhydrous CH 3 CN is added and the mixture stirred overnight.
• the mixture is diluted with 250 mL of EtOAc followed by 250 mL of sat. NH 4 Cl.
• 4-(2-Formyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester (0.50 g, 1.72 mmol) is dissolved in 80 mL of dioxane and 20 mL of H 2 O. The mixture is cooled to 4° C and then sulfamic acid (1.36 g, 14.00 mmol) is added in one portion. The mixture is stirred for an additional 30 min and then 3 mL of a solution of NaClO 2 (0.343 g, 3.80 mmol) is added in a drop-wise portion. The reaction is quenched by the addition of 50 mL of H 2 O and 50 mL of brine.
• 4-(2-Carboxy-phenyl)-piperazine-l-carboxylic acid tert-butyl ester (0.060 g, 0.195 mmol) is dissolved in 5 rnL of dry CH 2 Cl 2 under argon. The solution is cooled to 4° C and a 2 M solution of oxallyl chloride (0.10 rnL, 0.21 mmol) is added in a drop-wise fashion resulting in gas evolution. After stirring the mixture for 30 min, 1 drop of DMF is added and the mixture is stirred at room temperature for 30 min.
• the reaction mixture is cooled to 4° C and 4-trifluoromethyl-benzene-l,2-diamine (0.069 g, 0.390 mmol) and diisopropylethyl amine (0.092 mL, 0.500mmol) are added.
• the reaction is warmed to room temperature and stirred for Ih.
• the mixture is diluted with 50 mL EtOAc followed by 20 mL of sat. NH 4 Cl.
• the organic phase is washed with 2 x 20 mL of H 2 O and 1 x 20 mL of brine.
• the organic phase is dried with MgSO 4 , filtered and concentrated.
• the above benzamide (0.049 g, 0.090 mmol) is dissolved in 2 mL of CH 2 Cl 2 and placed in a microwave vial. A catalytic amount of p-TsOH is added and then the mixture is heated in the microwave oven for 20 min at 160° C. The mixture is then concentrated under a stream of N 2 .
• the crude coupling product from above is dissolved in trifluoroacetic acid (4 mL) and stirred at ambient temperature for 20 h. The reaction is concentrated in vacuo at 40 0 C to a residue. The reaction is diluted with DMF (2 mL) and water (1 mL) and purified by reverse-phase preparative HPLC (10-100% CH 3 CN/H 2 O) to give 24 mg of the title compound.
• reaction is diluted with DMF (1 mL) and water (1 rnL), quenched with trifluoroacetic acid (0.2 rnL) and purified by reverse-phase preparative HPLC (20-100% CH 3 CN/H 2 O) to give 51 mg of the title compound.
• the reaction is concentrated in vacuo at 40 0 C to a residue.
• the residue is diluted with DMF (2 mL), water (1 mL) and TFA (0.2 mL) and purified by reverse-phase preparative HPLC (10-100% CH 3 CN/H 2 O) to give 21 mg of the title compound.
• Compounds are assessed for the ability to block the interaction of CXCR3 and IP-10 in a functional cellular assay measuring calcium flux in CXCR3 transfected cells.
• Cyno-CHO cells, stably expressing recombinant CXCR3 and G-alpha-16 are grown in F 12 medium (Mediatech #45000-360) supplemented with 10% (V/V) FBS (Mediatech #35-01500), 1% Geneticin (Invitrogen # 10131-027) and 0.2% Zeocin (Invitrogen #R250-05).
• the cells are spun down and re-suspended in growth media to a concentration of 4.8 E5 cells/mL. 25 microL of cell suspension is added to each well of a BD-384-well TC treated plate, providing 12,000 cells/well. The plate is incubated at 37 °C/5% CO 2 overnight.
• the plates are removed, the media is flicked out and 25 microL of Ca-4 dye in assay buffer (HBSS, 10 mM HEPES ph 7.4), containing 2mM probenacid is added to each well.
• the cell assay plates are then incubated at 37 °C/5% CO 2 for one hour.
• Test compounds are dissolved in DMSO and diluted to 1.045 rnM in DMSO.
• 2.75 microL of appropriately diluted test compound are added to each well of a 384 well plate containing 45 microL of HBSS buffer. After mixing, 5 microL of diluted compound are added to each well of the cell assay plate for a final assay concentration of 10 microM.
• the plate is incubated at room temperature for 15 min. 10 microL of IP-IO stock solution in HBSS (4X EC80 concentration) are added to each well of the cell assay plate except those cells reserved as blank wells containing buffer only. Intracellular calcium flux is recorded on the HAMAMTSU FDSS6000, using excitation at 480 nm and emission at 540 nm. Data are analyzed using Activity Base software.
• the preferred potency range (IC 50 ) of compounds in the above assay is between 1 nM to 3 ⁇ M, and the most preferred potency range is 1 nM to 200 nM.
• the following table shows IC 50 S for representative compounds of the invention in the above assay.
• the compounds of the invention are effective antagonists of the interaction of CXCR3 and its ligands and thus inhibit CXCR3 activation. Therefore, in one embodiment of the invention, there is provided methods of treating CXCR3 -mediated disorders using compounds of the invention. In another embodiment, there is provided methods of treating inflammatory, autoimmune and cardiovascular diseases using compounds of the invention.
• the compounds of the invention block the migration of T-cells and other leukocytes that express CXCR3.
• the inhibition of CXCR3 activity is an attractive means for preventing and treating a variety of autoimmune and immunological diseases exacerbated by the influx of these leukocytes. These include multiple sclerosis, rheumatoid arthritis, psoriasis inflammatory bowel disease, chronic obstructive pulmonary disease (COPD) and kidney disease.
• COPD chronic obstructive pulmonary disease
• a genetic deletion study and a study in LDL receptor KO mice with a CXCR3 antagonist have both shown that inhibition of CXCR3 activity attenuates atherosclerotic lesion formation.
• inhibition of CXCR3 activity is also an attractive means for treating and preventing atherosclerosis and secondary atherothrombotic events such as myocardial infarction and stroke.
• a therapeutically effective dose will generally be in the range of approximately 0.01 mg to about 100 mg/kg of body weight per dosage of a compound of the invention; preferably, from about 0.1 mg to about 20 mg/kg of body weight per dosage.
• the dosage range would be approximately 0.7 mg to about 7000 mg per dosage of a compound of the invention, preferably from about 7.0 mg to about 1400 mg per dosage.
• Some degree of routine dose optimization may be required to determine an optimal dosing level and pattern.
• the active ingredient may be administered from 1 to 6 times a day.
• compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one compound of the invention.
• the compounds of the invention may also be administered alone or in combination with adjuvants that enhance stability of the compounds of the invention, facilitate administration of pharmaceutical compositions containing them in certain embodiments, provide increased dissolution or dispersion, increased antagonist activity, provide adjunct therapy, and the like.
• the compounds according to the invention may be used on their own or in conjunction with other active substances according to the invention, optionally also in conjunction with other pharmacologically active substances.
• the compounds of this invention are administered in a therapeutically or pharmaceutically effective amount, but may be administered in lower amounts for diagnostic or other purposes.
• Administration of the compounds of the invention, in pure form or in an appropriate pharmaceutical composition can be carried out using any of the accepted modes of administration of pharmaceutical compositions.
• administration can be, for example, orally, buccally (e.g., sublingually), nasally, parenterally, topically, transdermally, vaginally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as, for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
• the pharmaceutical compositions will generally include a conventional pharmaceutical carrier or excipient and a compound of the invention as the/an active agent, and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, vehicles, or combinations thereof.
• Such pharmaceutically acceptable excipients, carriers, or additives as well as methods of making pharmaceutical compositions for various modes or administration are well-known to those of skill in the art. The state of the art is evidenced, e.g., by Remington: The Science and Practice of Pharmacy, 20th Edition, A. Gennaro (ed.), Lippincott Williams & Wilkins, 2000; Handbook of Pharmaceutical
• the forms of the compounds of the invention utilized in a particular pharmaceutical formulation will be selected (e.g., salts) that possess suitable physical characteristics (e.g., water solubility) that are required for the formulation to be efficacious.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Immunology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Rheumatology (AREA)
• Physical Education & Sports Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Pain & Pain Management (AREA)
• Urology & Nephrology (AREA)
• Dermatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Vascular Medicine (AREA)
• Biomedical Technology (AREA)
• Plural Heterocyclic Compounds (AREA)
• Thiazole And Isothizaole Compounds (AREA)
• Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
• Hydrogenated Pyridines (AREA)
• Pyridine Compounds (AREA)
• Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
• Other In-Based Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (2)

Applications Claiming Priority (4)

Publications (1)

Family

ID=42313117

Family Applications (1)

Country Status (4)

Cited By (22)

Families Citing this family (2)

Citations (1)

Family Cites Families (19)

• 2010
  • 2010-04-26 JP JP2012507460A patent/JP5807971B2/ja active Active
  • 2010-04-26 WO PCT/US2010/032347 patent/WO2010126811A1/en not_active Ceased
  • 2010-04-26 EP EP10715470.0A patent/EP2424840B1/en active Active
  • 2010-04-27 US US12/768,268 patent/US8450317B2/en active Active

Patent Citations (1)

Non-Patent Citations (26)

Also Published As

Similar Documents

Legal Events